Evaluation of autologous fat injection as a minimally invasive technique for rectocele repair: a prospective pilot study.
Shafik IA., Abdelfatah MM., Shafik A., Hagagy E., Ali M.
Prospective Study with a reported sample of 25, published in Tech Coloproctol (2026) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- Tech Coloproctol (2026)
- Country
- Italy
- Reported sample size
- 25
- Source database
- PubMed
- PMID
- 42065829
- PMCID
- PMC13134980
- DOI
- 10.1007/s10151-026-03322-8
- NCT
- NCT06604702
Abstract (original English)
Rectocele repair remains challenging owing to high recurrence and morbidity associated with traditional surgical techniques. Autologous fat injection has emerged as a biologically integrative method that strengthens native pelvic tissues through regenerative mechanisms. This prospective pilot study evaluated feasibility, safety, and short-term anatomical and functional outcomes of autologous fat injection for rectocele repair. Between October 2023 and June 2025, 25 women with symptomatic Baden-Walker grade II-III rectocele and obstructed defecation syndrome (ODS) were prospectively enrolled at Kasr Al-Ainy Hospital, Cairo University. Abdominal fat was harvested, mechanically emulsified, and injected into the rectovaginal septum using a 15-gauge blunt cannula (mean injected volume 52 ± 10 mL). Outcomes included rectocele size on magnetic resonance (MR) defecography, clinical Baden-Walker grade, predefined ODS symptom categories/defecation frequency, and complications. Mean rectocele size decreased from 3.28 ± 0.82 to 1.82 ± 0.47 cm (p < 0.001). Overall, 80% of patients reported complete symptomatic improvement, while 20% reported recurrent symptoms during follow-up. Transient postoperative constipation occurred in 20% of patients and resolved conservatively. No major complications occurred. Injected volume showed an exploratory association with anatomical improvement. Autologous
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.